Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of ...

CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

Discover three undervalued biotech stocks with strong assets, solid cash reserves, and major catalysts ahead. Click for the ...

New research has identified cannabis-derived terpenes—compounds that give plants their distinctive aroma—as effective ...

Specifically, these molecules target the alpha-2A adrenergic receptor (ADRA2A), the serotonin 5-HT2C receptor and the dopamine transporter (DAT) – all of which play pivotal roles in neurological ...

In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...

Perspective Therapeutics, Inc. (NYSE: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient ...

YourChoice Therapeutics, Inc., pioneering hormone-free family planning products, announced today that Communications Medicine, a Nature Portfolio journal, has published a peer-reviewed paper on the ...

Bempikibart demonstrated positive, durable responses among patients with severe to very severe alopecia areata, according to ...

Perspective Therapeutics (NYSE:CATX – Get Free Report) will likely be posting its quarterly earnings results after the market ...

A recently completed study found that certain terpenes in Cannabis sativa are effective at relieving post-surgical and fibromyalgia pain in preclinical models.